Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02600897
Title A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

diffuse large B-cell lymphoma

follicular lymphoma

B-cell lymphoma

Therapies

Lenalidomide + Rituximab

Lenalidomide + Obinutuzumab

Lenalidomide + Polatuzumab vedotin-piiq + Rituximab

Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq

Age Groups: adult | senior
Covered Countries USA | ESP


No variant requirements are available.